The DOI matches its Crossref record; 157 of the 162 references it cites were found in a registry or an index.
RAS Proteins and Their Regulators in Human Disease
Open accessAbstract
RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear. All RAS biology occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, farnesylation at the position 185 cysteine residue results in KRAS anchoring at the plasma membrane, initiating the activation of KRAS and its downstream signaling42.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post-translational modification of KRAS plays an important role in KRAS–MAPK pathway activation.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS is one of the most frequently mutated oncogenes in cancer, yet efforts to directly target KRAS have been mostly unsuccessful because initial analyses of KRAS proteins indicated that they lack a clear pocket to which small molecules can bind with high affinity [1, 2].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Although KRAS mutations are often collectively classified as a single oncogenic entity, distinct KRAS alleles exhibit substantial biochemical and functional heterogeneity [1,4,12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [4]
In the citing paper
“Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“However, it is frequently mutated in only a handful of cancers, with the highest frequencies in colorectal adenocarcinoma (COAD), lung adenocarcinoma (LUAD), multiple myeloma (MM), and pancreatic adenocarcinoma (PAAD).”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“KRAS is one of the most commonly mutated genes in cancer1,2”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“When mutated at one of its four hotspot codons—12, 13, 61, or 146—activated KRAS protein hyperactivates many downstream effector pathways, such as the MAPK and PI3K-AKT signaling pathways1”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“As protein tyrosine phosphorylation plays an essential role in multiple intracellular processes, SHP2 is involved in the regulation of multiple signaling pathways, including those involved in cancer cells, such as RAS-MAPK, PI3K-AKT and JAK-STAT pathways.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“RAS acts as a molecular switch, transmitting signals of cell growth and differentiation by binding to GTP or GDP and switching between active and inactive states.261”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“The RAS family GTPases, KRAS, NRAS and HRAS, cycle between GTP-loaded ‘on’ and GDP-loaded ‘off’ states4,6, involving the action of RAS-guanine nucleotide exchange factors (RAS-GEFs) and RAS-GTPase-activating proteins (RAS-GAPs), respectively.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“Almost all cancer-associated RAS mutations (~95%) affect codon 12, 13 or 61, and lead to a markedly increased basal RAS-GTP:RAS-GDP ratio and constitutive activation of RAS effectors4,6.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“When mutated, oncogenic RAS remains preferentially in the active GTP-bound state, whereas GTP hydrolysis by its GTPase function and enzymes such as GTPase-activating proteins, is compromised1,2.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“These mutations dramatically shift the equilibrium of Ras protein to exist mostly in the GTP-bound state and effectively uncouple Ras proteins from upstream receptor inputs and drive constitutive signaling to downstream Ras effector pathways (13).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [13]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“Oncogenic KRAS can activate various downstream effector pathways, and the best characterized are phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) (23–25).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [24]
In the citing paper
“we recognize that these elements have a substantial influence on KRAS dynamics [53,54] and signaling [55].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
Martin, G. A., Viskoohil, D., Bollag, G. E., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90150-d · Cited by 983
Self-citationActivation of Raf as a Result of Recruitment to the Plasma Membrane
Stokoe, D., Macdonald, S. G., Cadwallader, K. A., Symons, M. H., & Hancock, J. F. (1994) · Science · doi:10.1126/science.7811320 · Cited by 976
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
PAI, E. F., Kabsch, W., Krengel, U., Holmes, K. C., John, J., & Wittinghofer, A. (1989) · Nature · doi:10.1038/341209a0 · Cited by 876
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850
Self-citationThe structural basis of the activation of Ras by Sos
Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Self-citationBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A. M., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P. O., Martin, S. C., Aschbacher‐Smith, L., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 704
Xu, G., Lin, B. K., Tanaka, K., Dunn, D. M., Wood, D. R., Gesteland, R. F., White, R. L., Weiss, R. B., & Tamanoi, F. (1990) · Cell · doi:10.1016/0092-8674(90)90149-9 · Cited by 681
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perišić, O., Lara‐González, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 611
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 603
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
The p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A. M., & Holland, E. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 554
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., DeSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540
Kaplan, D. R., Morrison, D. K., Wong, G. A., McCormick, F. P., & Williams, L. T. (1990) · Cell · doi:10.1016/0092-8674(90)90220-9 · Cited by 519
Self-citationDiscovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype
Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L. M., Schepper, S. D., Fryns, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2113 · Cited by 475
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Gutierrez, L., Magee, A. I., Marshall, C. J., & Hancock, J. F. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03478.x · Cited by 460
Cordeddu, V., Schiavi, E. D., Pennacchio, L. A., Ma’ayan, A., Sárközy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) · Nature Genetics · doi:10.1038/ng.425 · Cited by 429
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1
Uusitalo, E., Rantanen, M. E., Kallionpää, R. A., Pöyhönen, M., Leppävirta, J., Ylä‐Outinen, H., Riccardi, V. M., Pukkala, ., Pitkäniemi, J. M., Peltonen, S. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3576 · Cited by 423
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Krauthammer, M. O., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J. P., Ma, S., Cheng, E., Straub, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3361 · Cited by 417
RAF inhibitors that evade paradoxical MAPK pathway activation
Zhang, C., Spevak, W. R., Zhang, Y., Burton, E. A., Ma, Y., Habets, G. G. M., Zhang, J., Lin, J. Y.-S., Ewing, T. J. A., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 396
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., Raedt, T. D., Guney, I., Strochlic, D. E., MacConaill, L. E., Beroukhim, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2100 · Cited by 392
Easton, D. F., Ponder, M. A., Huson, S., & Ponder, B. A. J. (1993) · Europe PMC (PubMed Central) · Cited by 387
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Chio, I. I. C., Jafarnejad, S. M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.056 · Cited by 378
GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila
Bernards, A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00082-3 · Cited by 374
Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras
Ahmadian, M. R., Stege, P., Scheffzek, K., & Wittinghofer, A. (1997) · Nature Structural Biology · doi:10.1038/nsb0997-686 · Cited by 370
Recent advances in RASopathies
Aoki, Y., Niihori, T., Inoue, S., & Matsubara, Y. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.114 · Cited by 369
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368
Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis
Boyartchuk, V., Ashby, M. N., & Rine, J. (1997) · Science · doi:10.1126/science.275.5307.1796 · Cited by 361
DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras
Swarthout, J. T., Lobo, S., Farh, L., Croke, M., Greentree, W. K., Deschenes, R. J., & Linder, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504113200 · Cited by 356
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D. W., Widemann, B. C., Kim, M., Dombi, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 345
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T., Delrosario, R., Jen, K., Gurley, K. E., Kemp, C. J., et al. (2014) · Nature · doi:10.1038/nature13898 · Cited by 338
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338
Settleman, J. E., Narasimhan, V., Foster, L. C., & Weinberg, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90454-k · Cited by 333
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327
Self-citationChandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K‐ras(B).
Hancock, J. F., Cadwallader, K. A., & Marshall, C. J. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07992.x · Cited by 297
Mammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum
Dai, Q., Choy, E., Chiu, V. K., Romano, J. D., Slivka, S. R., Steitz, S. A., Michaelis, S., & Philips, M. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15030 · Cited by 296
Wildtype Kras2 can inhibit lung carcinogenesis in mice
Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L. T., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 295
Lipid-Sorting Specificity Encoded in K-Ras Membrane Anchor Regulates Signal Output
Zhou, Y., Prakash, P., Hong, L., Cho, K., Gorfe, A. A., & Hancock, J. F. (2016) · Cell · doi:10.1016/j.cell.2016.11.059 · Cited by 292
Shain, A. H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, Z., Chung, J., Wang, N. J., Kakavand, H., Mann, G. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3382 · Cited by 289
Inhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Divakar, S. K. A., Carpio, R. V., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L. A., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 278
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273
Self-citationSomatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Bremner, R., & Balmain, A. (1990) · Cell · doi:10.1016/0092-8674(90)90523-h · Cited by 264
Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243
Recurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229
Ras nanoclusters: Versatile lipid-based signaling platforms
Zhou, Y., & Hancock, J. F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.008 · Cited by 224
Ras membrane orientation and nanodomain localization generate isoform diversity
Abankwa, D., Gorfe, A. A., Inder, K. L., & Hancock, J. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903907107 · Cited by 223
Mazhab-Jafari, M. T., Marshall, C. B., Smith, M. J., Gasmi-Seabrook, G. M. C., Stathopulos, P. B., Inagaki, F., Kay, L. E., Neel, B. G., & Ikura, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419895112 · Cited by 220
Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., & McCormick, F. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.027 · Cited by 215
Self-citationYoung, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Self-citationXPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature · doi:10.1038/nature19771 · Cited by 202
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M. Z., Saunders, R. E., Melnick, M. A., Gettinger, S. N., Walther, Z., Wurtz, A., Heynen, G. J. J. E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 201
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199
K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Self-citationGenetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy
Mignot, C., von Stülpnagel, C., Nava, C., Ville, D. M., Sanlaville, D., Lesca, G., Rastetter, A., Gachet, B., Marie, Y., Korenke, G. C., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103451 · Cited by 189
Specificity in Ras and Rap Signaling
Raaijmakers, J. H., & Bos, J. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800061200 · Cited by 188
Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream Signaling
Villalonga, P., López-Alcalá, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J., Marais, R., Marshall, C. J., Bachs, O., & Agell, N. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7345-7354.2001 · Cited by 181
Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ
Dharmaiah, S., Bindu, L. K., Tran, T. H., Gillette, W., Frank, P. H., Ghirlando, R., Nissley, D. V., Esposito, D., McCormick, F. P., Stephen, A. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615316113 · Cited by 177
Self-citationRegulatory Proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3
Ohba, Y., Mochizuki, N., Yamashita, S., Chan, A. M.-L., Schrader, J. W., Hattori, S., Nagashima, K., & Matsuda, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000981200 · Cited by 168
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 168
Identification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín‐Gago, P., Kovačević, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K. F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 164
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Castellano, E., Sheridan, C., Thin, M. Z., Nye, E., Spencer-Dene, B., Diefenbacher, M., Moore, C., Kumar, M., Murillo, M., Grönroos, E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 161
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1Preprint
Stowe, I. B., Mercado, E. L., Stowe, T. R., Bell, E. L., Osés-Prieto, J. A., Hernández, H., Burlingame, A. L., & McCormick, F. P. (2012) · Genes & Development · doi:10.1101/gad.190876.112 · Cited by 158
Self-citationProteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis
McGillicuddy, L. T., Longo, J. F., Hollstein, P. E., Kubek, S., Beroukhim, R., Raedt, T. D., Johnson, B. W., Williams, S. M. G., Nghiemphu, P. L., Liau, L. M., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.009 · Cited by 158
H-Ras forms dimers on membrane surfaces via a protein–protein interface
Lin, W., Iversen, L., Tu, H., Rhodes, C., Christensen, S. M., Iwig, J. S., Hansen, S. D., Huang, W. Y. C., & Groves, J. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321155111 · Cited by 156
Fivaz, M., & Meyer, T. (2005) · Journal of Cell Biology · doi:10.1083/jcb.200409157 · Cited by 154
Formation of the Ras Dimer Is Essential for Raf-1 Activation
Inouye, K., Mizutani, S., Koide, H., & Kaziro, Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3737 · Cited by 154
Gripp, K. W., Aldinger, K. A., Bennett, J. T., Baker, L., Tusi, J., Powell‐Hamilton, N., Stabley, D. L., Sol‐Church, K., Timms, A. E., & Dobyns, W. B. (2016) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37781 · Cited by 152
Three Separable Domains Regulate GTP-Dependent Association of H-ras with the Plasma Membrane
Rotblat, B., Prior, I. A., Muncke, C., Parton, R. G., Kloog, Y., Henis, Y. I., & Hancock, J. F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6799-6810.2004 · Cited by 150
N-Ras Forms Dimers at POPC Membranes
Güldenhaupt, J., Rudack, T., Bachler, P. S., Mann, D., Triola, G., Waldmann, H., Kötting, C., & Gerwert, K. B. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.08.043 · Cited by 148
Grabocka, E., Pylayeva‐Gupta, Y., Jones, M. V., Lubkov, V., Yemanaberhan, E., Taylor, L. J., Jeng, H. H., & Bar‐Sagi, D. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.005 · Cited by 144
Membrane-Mediated Induction and Sorting of K-Ras Microdomain Signaling Platforms
Weise, K., Kapoor, S., Denter, C., Nikolaus, J., Opitz, N., Koch, S., Triola, G., Herrmann, A., Waldmann, H., & Winter, R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107532q · Cited by 143
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B. T., Raedt, T. D., Lim, E., Bronson, R. T., Beroukhim, R., Polyák, K., Brown, M. A., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 137
Prakash, P., Zhou, Y., Hong, L., Hancock, J. F., & Gorfe, A. A. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.01.019 · Cited by 135
Pathogenetics of the RASopathies
Tidyman, W. E., & Rauen, K. A. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw191 · Cited by 133
Jeyabalan, N., & Clement, J. P. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00032 · Cited by 130
Ballester, R., Furth, M. E., & Rosen, O. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61562-5 · Cited by 129
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
Chang, T. Y., Krisman, K., Theobald, E. H., Xu, J., Akutagawa, J., Lauchle, J., Kogan, S. C., Braun, B. S., & Shannon, K. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63193 · Cited by 126
Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1
Morris, S. M., Acosta, M. T., Garg, S., Green, J., Huson, S., Legius, E., North, K. N., Payne, J. M., Plasschaert, E., Frazier, T. W., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2600 · Cited by 122
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121
Young, L. C., Hartig, N., Muñoz-Alegre, M., Osés-Prieto, J. A., Durdu, S., Bender, S., Vijayakumar, V., Rudan, M. V., Gewinner, C. A., Henderson, S. R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.004 · Cited by 119
HRAS and the Costello syndrome
Rauen, K. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00743.x · Cited by 119
Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit
Ritt, D. A., Abreu‐Blanco, M. T., Bindu, L. K., Durrant, D., Zhou, M., Specht, S. I., Stephen, A. G., Holderfield, M. T., & Morrison, D. K. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.029 · Cited by 118
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
To, M. D., Wong, C. E., Karnezis, A. N., Rosario, R. D., Lauro, R. D., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
Self-citationMembrane-Mediated Induction and Sorting of K-Ras Microdomain Signaling Platforms
Weise, K., Kapoor, S., Denter, C., Nikolaus, J., Opitz, N., Koch, S., Triola, G., Herrmann, A., Waldmann, H., & Winter, R. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2010.12.689 · Cited by 112
Recurrent inactivating RASA2 mutations in melanoma
Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3427 · Cited by 107
Weise, K., Triola, G., Brunsveld, L., Waldmann, H., & Winter, R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja808691r · Cited by 102
Human Gene Mutation Database: towards a comprehensive central mutation database
Stenson, P. D., Ball, E., Howells, K., Phillips, A. D., Mort, M. E., & Cooper, D. N. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.055210 · Cited by 102
Quinlan, M. P., Quatela, S. E., Philips, M. R., & Settleman, J. E. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01661-07 · Cited by 96
Paulson, V., Shivdasani, P., Angell, T. E., Cibas, E. S., Krane, J. F., Lindeman, N. I., Alexander, E. K., & Barletta, J. A. (2017) · Thyroid · doi:10.1089/thy.2016.0583 · Cited by 96
The importance of Raf dimerization in cell signaling
Freeman, A. K., Ritt, D. A., & Morrison, D. K. (2013) · Small GTPases · doi:10.4161/sgtp.26117 · Cited by 95
Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy
Higgins, E. M., Bos, J. M., Mason‐Suares, H., Tester, D. J., Ackerman, J. P., MacRae, C. A., Sol‐Church, K., Gripp, K. W., Urrutia, R. A., & Ackerman, M. J. (2017) · JCI Insight · doi:10.1172/jci.insight.91225 · Cited by 95
Genotype-phenotype correlations of amyotrophic lateral sclerosis
Li, H., & Wu, Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0050-8 · Cited by 94
Mosaic Neurofibromatosis Type 1: A Systematic Review
García‐Romero, M. T., Parkin, P. C., & Lara‐Corrales, I. (2015) · Pediatric Dermatology · doi:10.1111/pde.12673 · Cited by 92
Structures of Ras superfamily effector complexes: What have we learnt in two decades?
Mott, H. R., & Owen, D. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.999191 · Cited by 89
Ullrich, M., Weber, M., Post, A. M., Popp, S., Grein, J., Zechner, M., González, H. G., Kreis, A., Schmitt, A. G., Üçeyler, N., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.232 · Cited by 89
RAS interaction with PI3K p110α is required for tumor-induced angiogenesis
Murillo, M. M., Zelenay, S., Nye, E. L., Castellano, E., Lassailly, F., Stamp, G., & Downward, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74134 · Cited by 88
RalGDS family members couple Ras to Ral signalling and that's not all
Ferro, E., & Trabalzini, L. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.05.010 · Cited by 87
Sung, P. J., Tsai, F. D., Vais, H., Court, H., Yang, J., Fehrenbacher, N., Foskett, J. K., & Philips, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306431110 · Cited by 86
Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis
To, M. D., Rosario, R. D., Westcott, P. M. K., Banta, K. L., & Balmain, A. (2012) · Oncogene · doi:10.1038/onc.2012.404 · Cited by 82
Alvarez-Moya, B., López-Alcalá, C., Drosten, M., Bachs, O., & Agell, N. (2010) · Oncogene · doi:10.1038/onc.2010.298 · Cited by 75
The higher level of complexity of K‐Ras4B activation at the membrane
Jang, H., Banerjee, A., Chavan, T., Lu, S., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · The FASEB Journal · doi:10.1096/fj.15-279091 · Cited by 75
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J. R., Jacks, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0096 · Cited by 68
Kapoor, S., Weise, K., Erlkamp, M., Triola, G., Waldmann, H., & Winter, R. (2012) · European Biophysics Journal · doi:10.1007/s00249-012-0841-5 · Cited by 67
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers
Olsen, S. N., Wronski, A., Castaño, Z., Dake, B. T., Malone, C. F., Raedt, T. D., Enos, M., DeRose, Y. S., Zhou, W., Guerra, S. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0520 · Cited by 67
The Lipid Modifications of Ras that Sense Membrane Environments and Induce Local Enrichment
Vogel, A., Reuther, G., Weise, K., Triola, G., Nikolaus, J., Tan, K., Nowak, C., Herrmann, A., Waldmann, H., Winter, R., et al. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903396 · Cited by 66
Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66
Dunzendorfer-Matt, T., Mercado, E. L., Maly, K., McCormick, F. P., & Scheffzek, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607298113 · Cited by 63
Self-citationIndependent NF1 and PTPN11 mutations in a family with neurofibromatosis‐Noonan syndrome
Thiel, C. T., Wilken, M., Zenker, M., Sticht, H., Fahsold, R., Gusek-Schneider, G.-C., & Rauch, A. M. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32837 · Cited by 62
Regulation of K-Ras4B Membrane Binding by Calmodulin
Sperlich, B., Kapoor, S., Waldmann, H., Winter, R., & Weise, K. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.05.042 · Cited by 49
Membrane orientation dynamics of lipid-modified small GTPases
Prakash, P., & Gorfe, A. A. (2016) · Small GTPases · doi:10.1080/21541248.2016.1211067 · Cited by 48
T-Cell Transfer Therapy Targeting Mutant KRAS
Maoz, A., Rennert, G., & Gruber, S. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616637 · Cited by 43
Lusk, J. B., Lam, V. Y. M., & Tolwinski, N. S. (2017) · Cancers · doi:10.3390/cancers9020016 · Cited by 38
Phosphorylation Weakens but Does Not Inhibit Membrane Binding and Clustering of K-Ras4B
Zhang, S.-Y., Sperlich, B., Li, F.-Y., Al-Ayoubi, S. R., Chen, H.-X., Zhao, Y., Li, Y., Weise, K., Winter, R., & Chen, Y. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00165 · Cited by 38
PTPN11 and KRAS Gene Analysis in Patients with Noonan and Noonan-Like Syndromes
Brasil, A. S., Pereira, A. C., Wanderley, L. T., Kim, C. A., Malaquias, A. C., Jorge, A. A. L., Krieger, J. E., & Bertola, D. R. (2010) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2009.0192 · Cited by 37
Sorafenib‐induced premalignant and malignant skin lesions
Williams, V. L., Cohen, P. R., & Stewart, D. J. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04822.x · Cited by 36
pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins
Prakash, P., Sayyed–Ahmad, A., & Gorfe, A. A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004469 · Cited by 36
Ekvall, S., Hagenäs, L., Allanson, J. E., Annerén, G., & Bondeson, M.-L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33987 · Cited by 29
Functional Genomic Characterization of Cancer GenomesPreprint
Howard, T. P., Vázquez, F., Tsherniak, A., Hong, A. L., Rinne, M. L., Aguirre, A. J., Boehm, J. S., & Hahn, W. C. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031070 · Cited by 24
Biochemical and Structural Insights into the Aminotransferase CrmG in Caerulomycin Biosynthesis
Zhu, Y., Xu, J., Mei, X., FENG, Z., Zhang, L., Zhang, Q., Zhang, G., Zhu, W., Liu, J., & Zhang, C. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00984 · Cited by 23
Phenotypic variability among café-au-lait macules in neurofibromatosis type 1
Boyd, K. P., Gao, L., Feng, R., Beasley, T. M., Messiaen, L. M., Korf, B. R., & Theos, A. J. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.042 · Cited by 20
Brasil, A. S., Malaquias, A. C., Wanderley, L. T., Kim, C. A., Krieger, J. E., Jorge, A. A. L., Pereira, A. C., & Bertola, D. R. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000800009 · Cited by 19
Bayrak‐Toydemir, P., & Stevenson, D. A. (2013) · University of Washington, Seattle eBooks · Cited by 17
T-Cell Transfer Therapy Targeting Mutant KRAS.
Rosenberg, S. A., Tran, E., & Robbins, P. F. (2017) · PubMed · Cited by 16
Erwin, N., Sperlich, B., Garivet, G., Waldmann, H., Weise, K., & Winter, R. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp00563b · Cited by 11
Clinical and historical aspects of the Elephant Man: Exploring the facts and the myths
Huntley, C., Hodder, A., & Ramachandran, M. (2014) · Gene · doi:10.1016/j.gene.2014.09.056 · Cited by 10
Genetic analysis of ras homologs in yeasts.
Powers, S. (1992) · PubMed · Cited by 9
Flagged first, then by citations
5 of the 162 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Autophagy and autophagy-related pathways in cancer
Debnath, J., Gammoh, N., & Ryan, K. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00585-z · Cited by 1,506
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Metadata
- Authors
- Simanshu, D. K., Nissley, D. V., & McCormick, F.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- University of California, San Francisco (US)
- Corresponding author
- McCormick, Frank
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 170
- Issue
- 1
- Pages
- 17-33
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5555610
- OpenAlex
- W2732767128
- Cited by
- 1,943
- References
- 162
- Citations by year
- 2026: 210 · 2025: 263 · 2024: 276 · 2023: 247 · 2022: 267 · 2021: 247 · 2020: 194 · 2019: 143 · 2018: 82 · 2017: 12
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute
- NIH (HHSN261200800001E)
- Outstanding Investigator Award (5R35CA197709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras proteins, Ras signaling, RASopathies, cancer, mental illness, RAS mutations, signal transduction, membrane binding, Ras activation
- MeSH terms
- Congenital Abnormalities, Animals, Mental Disorders, Cell Membrane, Humans, Mutation, Neoplasms, Phylogeny, Yeasts, Signal Transduction, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
